This trial is evaluating whether Treatment will improve 1 primary outcome, 5 secondary outcomes, and 4 other outcomes in patients with Eczema. Measurement will happen over the course of Week 12.
This trial requires 120 total participants across 2 different treatment groups
This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
While eczema cannot be cured, its severity can be significantly reduced with suitable treatment. Patients should be aware that there are effective treatments for most eczematous conditions, provided that their condition becomes properly diagnosed.
There is no single environmental cause of eczema and it results from a combination of environmental and individual factors. Exposure to certain kinds of pollutants appear to be one of the major factors in the causation of eczema, especially allergic eczema.\n
A major portion of the patients in our sample had no medications at all. Most of the patients who reported using medicines did so cautiously and experienced only limited success. A substantial proportion of the women reported use of medication at least in the past for at least 3 weeks. Most of the patients had one or more of the following triggers for an eczematous response: allergens, infection, occupational exposures, stress, cold weather, sunlight, stress, emotional stress, dehydration, excessive drinking, smoking, drugs, or any combination of them.
About 5% of US children (14--19.9 million) are afflicted by atopic dermatitis, which accounts for over 25 million office visits per year. It may be prudent for physicians to consider treatment options in atopy-prone children with moderate-to-high severity of dermatitis.
There are various signs and symptoms of eczema. Each clinical manifestation of eczema has its own characteristic signs and symptoms that can be identified to the dermatologist.\n
Eczema affects approximately 20% of people aged 3-4 and is a major cause of childhood and school absenteeism. It has a range of severity, presenting as mild, moderate or severe disease. Eczema can disrupt the normal life of children and family members. It is important to consider eczema as an illness as the impact on quality of life can be substantial. In a recent study, findings showed that there is significant variation in the severity of eczema across different family and individual characteristics and that the severity can be estimated easily.
Eczema is caused by various mechanisms, some of which have a genetic basis, while others are lifestyle related. The use of sun protective clothing reduces the risk of developing eczema in children and young adults. This reduces the effects of solar radiation. A genetic component to eczema seems unlikely. For most children the cause of eczema is unknown and therefore there are no conclusive answers available to date.
I've tried everything for eczema - from using salicylates to using salicylic acid. Everything I used hasn't proven effective for me but the key to most good treatments that have failed for me is to find the correct amount (and type) of medication. And for eczema (and everything else) you need a good practitioner who has all the tools for the job - one who can work with you to find the right drug and amount to match your needs.\n
The majority of respondents said that their eczema had a moderate to very small improvement, with a significant minority having a completely unaltered condition. We observed no major adverse events during the survey period. The potential for severe infection with treatment is also an important consideration, as is the potential for adverse drug reactions with the use of the topical medications. However, further research is needed to assess the safety of medications used, to assess the risk of infection with treatments and to identify the risks of treatment, particularly if this involves steroids.
A combination of topical and systemic treatments is the most common treatment approach. Topical medications have proven to be more effective than a placebo in treatment of localized acute flares of eczema, or in decreasing the need for multiple topical therapies
The patients reported that they were taking several complementary treatments, almost exclusively OTC. This finding highlights the need to make treatment of allergic rhinitis more integrated when treating severe to debilitating symptoms.
The disease commonly occurs between the ages of 3 and 6 years old. People between the ages of 6 and 15 tend to be more severe cases. Most severe cases appear between the ages of 16 and 50. The rate of occurrence varies by population based on age. In Western countries, the disease occurs most frequently between the ages of 0 and 3 years. In China, the disease occurs the most commonly between the ages of 6 and 18 years. In the United Kingdom, the disease is more commonly seen between the ages of 3 and 6 years old. In the United States, the disease is most commonly seen between the ages of 0 and 3 years old but it tends to occur more aggressively in older people.